Login / Signup

A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer.

Can ChenMinjun ChenYuju BaiYajun LiJie PengBiao YaoJiangping FengJian-Guo ZhouHu Ma
Published in: Technology in cancer research & treatment (2024)
NCT05901584.
Keyphrases
  • phase ii
  • clinical trial
  • small cell lung cancer
  • open label
  • double blind
  • phase iii
  • placebo controlled
  • study protocol
  • combination therapy
  • smoking cessation